Background. Overactive bladder (OAB), a symptom syndrome defined as urgency, is a common clinical condition, which sometimes cannot be satisfactorily treated with current medications in every subject; therefore, alternatives are needed.
Introduction
The urinary bladder is a distensible, membranous, hollow organ, made of a thin layer of smooth muscle that provides its unique properties of relaxing to accommodate and contracting to empty out urine, one of the body's continuously produced fluid waste products. The smooth muscle wall of the bladder, also known as the detrusor, and the internal sphincter, the internal continuation of the detrusor, are under autonomic control, while the external urethral sphincter is under somatic control from higher centers. 1 The bladder temporarily stores urine until the person finds appropriate time and place to eliminate it from the body by coordinated actions of autonomic and somatic muscles that encircle the bladder neck. 2 Thus, the process of physiological control of urination, notably the reflex contraction of the detrusor muscle, involves highly complex coordination between the central, autonomic and somatic nervous systems, and has been reviewed extensively elsewhere. 3, 4 As the bladder fills up with urine and its volume reaches about 200 mL or more (bladder functional capacity is 300-600 mL), the stretch receptors in the bladder excite and send signals to higher centers, and the voluntary voiding is usually initiated. However, the detrusor can become too active and contract involuntarily, making the individual feel the urge to void inappropriately, even when the bladder has little urine. This clinical symptom is referred to as overactive bladder (OAB), typically caused by spasms of the bladder muscles with or without incontinence. 5 Overactive bladder is a very common chronic condition that affects the daily lives of a huge number of men, women and children worldwide. 5, 6 Urinary urgency, frequent urination and nocturia are a common set of OAB symptoms that can be caused by a wide range of conditions, including detrusor hyperreflexia, urinary tract infections and obstructive prostatic hypertrophy. 5, 6 Whatever the underlying cause, intense and involuntary bladder muscle contractions are present. Although symptoms can range in severity from mild to very severe, OAB is a condition that often requires treatment. And, despite a range of available treatment options, just as the etiology of OAB is often multifactorial, the treatment approaches and available tools are far from satisfactory.
Basic research studies of isolated bladder smooth muscle tissue have made important contributions to our current understanding of the physiology of the bladder, as well as the development of new and improved approaches for the control of clinically relevant detrusor contractility impairments, ranging from underactivity to overactivity, including OAB.
The "funny" (If) current (or funny channel or pacemaker current), originally described in the sinoatrial (SA) node and Purkinje fibers, is currently being investigated for its potential role(s) in smooth muscles with the capacity of generating spontaneous phasic activity. [7] [8] [9] [10] 11 Evidence is being accumulated that interstitial cells of Cajal (ICCs) and ICC-like cells possess the general and specific properties of pacemaker cells. Although less studied than those in cardiac tissue, they are ubiquitously expressed in smooth muscle tissues of many organs, including the gastrointestinal tract, uterine, lymph ducts, urinary bladder, and urethra. 8, 9 The pacemaker structures have been suggested to contribute to spontaneous contractions of these smooth muscle tissues by funny currents (If currents) through hyperpolarization-activated cyclic nucleotide-gated (HCN) channels. 9, 12 Indeed, the self-contractibility of the urinary bladder through myogenic excitation implicates a potential bladder pacemaker, possible through the signals from ICCs. Interstitial cells of Cajal, a group of cells present in the wall of the bladder, are suggested to play a role in OAB, although there is no clear evidence of signal transmission. Still, the results of a clinical study have implied that the use of ivabradine, a selective blocker of pacemaker If current, could possibly be used in the treatment of OAB. 13 However, studies involving the possible effects of ivabradine on smooth muscle contractility have never been carried out.
Hence, the aim of this in vitro study was to investigate the possible effects of ivabradine on agonist-stimulated contractions of isolated rat bladder smooth muscles.
Material and methods

Tissue preparation
The protocol of this study was reviewed and approved by the local Ethics Committee.
Adult male Wistar rats (250-300 g), obtained from the Karadeniz Technical University Surgical Research Center, Trabzon, Turkey, were sacrificed by cervical dislocation, and the urinary bladder was exposed by a midline incision of the abdomen. The urinary bladder was removed by cutting at the bladder neck and placed in a physiological saline solution (PSS) containing: 120 mM NaCl, 5.9 mM KCl, 2.5 mM CaCl 2 , 1.1 mM MgCl 2 , 15 mM NaHCO 3 , 1.2 mM NaH 2 PO 4 , 11 mM C 6 H 12 O 6 (glucose), and 10 mM C 8 H 18 N 2 O 4 S (HEPES). The bladder was cut open from the base to the dome and strips were prepared (~15 mm × 3 mm × 2 mm).
Recording of isometric tension
Bladder strips were mounted in 10 mL organ baths filled with PSS at 37°C and pH 7.4, constantly bubbled with 95% oxygen-5% carbon dioxide, and the isometric contractions were recorded. The lower end of the strip was fixed to a metal hook and the upper end was attached to an isometric force-displacement transducer (FTD 10A; Commat Ltd., Ankara, Turkey), and the signals were amplified and recorded through a data acquisition system (MP100 Data Acquisition System; Biopac Systems Inc., Goleta, USA).
The strips were allowed to equilibrate under a passive resting tension of 1 g for 45 min, and then the strips were contracted by bath applications of carbachol (CCh, 1 µM). Ivabradine (30 µM, 60 µM and 90 µM) was added to the tissue bath either prior to or after application of the agonist, and the resulting contractile activity was compared with the preceding contractile activity. The amplitude and area under force-time curves (AUFC) of the isometric contractions were evaluated and compared, averaged over 10-minute intervals.
Chemicals
Ivabradine, CCh and all constituents of the PSS were purchased from Sigma (Deisenhofen, Germany) and were of research grade. Ivabradine and CCh were dissolved in the PSS, and were added to the tissue bath at the indicated concentrations.
Statistical analysis
All statistical analyses and graphics were performed using the Microcal Origin v. 5.00 computer program (Microcal Software Inc., Northampton, USA). The data is expressed as the arithmetic mean of the "n" number of experiments and the standard error of mean (SEM). Statistical significance was analyzed by Student's t-test. The probability value of p < 0.05 was considered significant.
Results
In 3 out of the 22 strips studied, the bath application of CCh caused a marked stimulation of contractile force in isolated bladder strips. The remaining non-responding 3 strips were not further utilized for the study.
The application of ivabradine attenuated the peak amplitude of the CCh-induced contractions in a concentration-dependent manner. The peak amplitude of the contractions was reduced to 29% ±3% (p < 0.001), 20% ±6% (p < 0.001) and 18% ±6% (p < 0.001) of the CCh-induced period (100%) after the application of 30 µM, 60 µM and 90 µM ivabradine, respectively ( Fig. 1-3) . Ivabradine caused a similar attenuation in the AUFC values for CChevoked contractile responses. On the average, the normalized AUFC values of CCh-induced contractions was reduced to 47% ±5.5% (p < 0.01), 35% ±8% (p < 0.01) and 35% ±6% (p < 0.01) (n = 7 for each) of the CCh-induced period (100%) after the application of 30 µM, 60 µM and 90 µM ivabradine, respectively ( Fig. 1-3) .
In additional experiments, the strips of bladder were pre-treated with ivabradine. Pre-treatment with ivabradine significantly inhibited the contractile response to CCh without significantly effecting the resting tension ( Fig. 4) . Accordingly, ivabradine (10 µM) was applied before CChstimulation (1 µM), and the mean peak amplitude of these contractions were significantly weaker when compared to the contractile response to CCh alone (680 ±95 mg, n = 7 vs 1493 ±216 mg; n = 7; p < 0.003) ( Fig. 4 ).
Discussion
The results of the present in vitro study demonstrated, for the first time, that ivabradine inhibits cholinergic agonist-induced contraction of the rat bladder. This is the first evidence that the If channel inhibitor -ivabradine directly blocks bladder muscle contractility, implying that it might be useful in the treatment of OAB. Results are expressed as mean ±SE; * p < 0.01 compared to the CCh-induced response period prior to ivabradine application (n = 7); ** p < 0.001 compared to the CCh-induced response period prior to ivabradine application (n = 7).
A representative tracing illustrating the contractile activity of bladder strip preparations in response to carbachol (CCh, 1 μM) and the inhibition of the contractile activity by ivabradine. Bladder strips developed a sustained tension in response to CCh, and ivabradine was applied at the indicated point and was continuously present afterwards. Interstitial cells of Cajal play an important role in the regulation of the bladder excitation-contraction process, probably by providing the link between the neurogenic and myogenic mechanisms. The finding that normally single in nature ICCs predominantly appear as closely joined in unstable bladders, and the presence of a strong correlation between the density of ICCs and detrusor excitability further indicates this possibility. 14 Furthermore, following spinal cord injury, which typically leads to a neurogenic bladder exhibiting urinary retention, there is a significantly lower number of ICCs in the rat urinary bladder. 15, 16 The HCN channels, which generate pacemaking currents, are present on the cell membranes of ICCs. Considering all these facts, it could be postulated that pacemaker current inhibitors might be useful in the treatment of OAB. In the present in vitro study, the amplitude of CCh-induced contractions of rat bladder strips was inhibited by ivabradine in a concentrationdependent manner.
Similar to previous the in vitro studies using detrusor smooth muscles, the application of muscarinic receptor agonist CCh (1 µM) evoked strong sustained tonic contractions. 17, 18 In cultured ICCs, the in vitro application of CCh was shown to cause an increase in intracellular calcium, intracellular signaling essential for the generation of pacemaker potentials and contraction, suggesting that bladder ICCs might play a role in the regulation of cholinergic stimulation-mediated bladder contraction. [18] [19] [20] Although this information can help in the interpretation of the ivabradine effect on bladder contractility, we do not know whether the inhibitory effect of ivabradine obtained in the current study is mediated through ICCs. Although we have no direct evidence, the inhibitory actions of ivabradine on the rat detrusors might involve the modulation Results are expressed as mean ±SE; * p < 0.01 compared to the CChinduced response period prior to ivabradine application (n = 7); ** p < 0.001 compared to the CCh-induced response period prior to ivabradine application (n = 7).
A representative tracing illustrating the contractile activity of bladder strip preparations in response to carbachol (CCh, 1 μM) and the inhibition of the contractile activity by ivabradine. Bladder strips developed a sustained tension in response to CCh, and ivabradine was applied at the indicated point and was continuously present afterwards. of calcium release from the sarcoplasmic reticulum (SR). This is plausible, considering the role of Ca 2+ released from the SR in regulating If in SA node preparations. 21 In bladder overactivity, developed in a rat model following partial bladder outlet obstruction, it was shown that the physiological functioning of ICCs changes and the expression of the HCN channels in bladder ICCs significantly increases. [22] [23] [24] These findings suggest that the HCN channels and ICCs might play an important role in the pathogenesis of detrusor overactivity. Thus, the involvement of the HCN channels is another possible mechanism mediating the inhibition of cholinergic agonist-induced bladder contraction by ivabradine. Considering this structural evidence, our findings of the inhibitory effect of ivabradine on CChinduced bladder contractility would be of importance in the management of OAB.
The concentrations of ivabradine tested in the present study are higher (about 100-fold) than its achieved max plasma concentration, following the recommended dose of 5 mg twice daily. This concentration is well-below the toxic dose reported in animal studies, although there is not enough clinical data revealing special hazards for humans. 25 In a case of a purposeful intoxication attempt with 280 mg of ivabradine, no serious complication, other than mild bradycardia, which was no more severe than the one observed with a therapeutic dosage, was reported. 26 In any case, lower doses of ivabradine could be used in combination with available drugs (i.e., anticholinergics) that would provide efficacy and minimize the risk of unwanted effects.
Conclusions
In conclusion, the results of this in vitro study demonstrate that ivabradine inhibits cholinergic agonist-induced bladder contractions. It shows that ivabradine could be potentially used in the future, alone or in combination with currently used agents (i.e., anticholinergic) in OAB treatment. 
